Abstract

Purpose: The purpose of this study was to compare the diagnostic performance of breast lesions between deep learning-based computer-aided diagnosis (deep learning-based CAD) system and experienced radiologists and to compare the performance between symptomatic and asymptomatic patients.Methods: From January to December 2018, a total of 451 breast lesions in 389 consecutive patients were examined (mean age 46.86 ± 13.03 years, range 19–84 years) by both ultrasound and deep learning-based CAD system, all of which were biopsied, and the pathological results were obtained. The lesions were diagnosed by two experienced radiologists according to the fifth edition Breast Imaging Reporting and Data System (BI-RADS). The final deep learning-based CAD assessments were dichotomized as possibly benign or possibly malignant. The diagnostic performances of the radiologists and deep learning-based CAD were calculated and compared for asymptomatic patients and symptomatic patients.Results: There were 206 asymptomatic screening patients with 235 lesions (mean age 45.06 ± 10.90 years, range 21–73 years) and 183 symptomatic patients with 216 lesions (mean age 50.03 ± 14.97 years, range 19–84 years). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy and area under the receiver operating characteristic curve (AUC) of the deep learning-based CAD in asymptomatic patients were 93.8, 83.9, 75.0, 96.3, 87.2, and 0.89%, respectively. In asymptomatic patients, the specificity (83.9 vs. 66.5%, p < 0.001), PPV (75.0 vs. 59.4%, p = 0.013), accuracy (87.2 vs. 76.2%, p = 0.002) and AUC (0.89 to 0.81, p = 0.0013) of CAD were all significantly higher than those of the experienced radiologists. The sensitivity (93.8 vs. 80.0%), specificity (83.9 vs. 61.8%,), accuracy (87.2 vs. 73.6%) and AUC (0.89 vs. 0.71) of CAD were all higher for asymptomatic patients than for symptomatic patients. If the BI-RADS 4a lesions diagnosed by the radiologists in asymptomatic patients were downgraded to BI-RADS 3 according to the CAD, then 54.8% (23/42) of the lesions would avoid biopsy without missing the malignancy.Conclusion: The deep learning-based CAD system had better performance in asymptomatic patients than in symptomatic patients and could be a promising complementary tool to ultrasound for increasing diagnostic specificity and avoiding unnecessary biopsies in asymptomatic screening patients.

Highlights

  • Breast cancer is a leading cause of cancer-related mortality in women worldwide [1]

  • SE, sensitivity; SP, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; PPV, positive predictive value; NPV, negative predictive value; areas under the ROC curves (AUCs), area under the receiver operator characteristics curve; 95% CI, 95% confidence interval

  • If the Breast Imaging Reporting and Data System (BI-RADS) 4a lesions diagnosed by the radiologists in asymptomatic patients were downgraded to BIRADS 3 according to the computer-aided diagnosis (CAD) system results, 54.8% (23/42) of the lesions would avoid biopsy without missing the 2 malignant tumors

Read more

Summary

Introduction

Breast cancer is a leading cause of cancer-related mortality in women worldwide [1]. As an important supplementary modality for mammography, ultrasound plays an important role in dense breast tissue. A multicenter randomized trial across China compared ultrasound and mammography for breast cancer screening in high-risk Chinese women and showed that ultrasound had a significantly higher sensitivity and accuracy than mammography [2]. Ultrasound is widely used as the primary screening modality for breast cancer in China [3]. Ultrasounds often lead to a certain number of false-positive lesions and unnecessary biopsies or surgeries because ultrasound has low specificity and positive predictive value (PPV) [4,5,6]. This has become an urgent problem of ultrasound in breast cancer screening in China

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call